Researchers uncover potentially promising therapeutic combination for renal cell carcinoma
(Beth Israel Deaconess Medical Center) Investigators have demonstrated that ACE2 expression is a good prognostic factor in RCC, that loss of ACE2 mediates resistance to classical treatments, and that in preclinical models, treatment with a drug that is downstream of ACE2 can improve tumor responses in RCC and significantly prolong survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 20, 2021 Category: Cancer & Oncology Source Type: news

A metabolic shift into kidney cancer
(Source: ScienceNOW)
Source: ScienceNOW - January 7, 2021 Category: Science Authors: Wong, W. Tags: twis Source Type: news

Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer
Understanding the mechanisms of the Warburg shift to aerobic glycolysis is critical to defining the metabolic basis of cancer. Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an aggressive cancer characterized by biallelic inactivation of the gene encoding the Krebs cycle enzyme fumarate hydratase, an early shift to aerobic glycolysis, and rapid metastasis. We observed impairment of the mitochondrial respiratory chain in tumors from patients with HLRCC. Biochemical and transcriptomic analyses revealed that respiratory chain dysfunction in the tumors was due to loss of expression of mitochondrial DNA (mtDNA)&n...
Source: Signal Transduction Knowledge Environment - January 5, 2021 Category: Science Authors: Crooks, D. R., Maio, N., Lang, M., Ricketts, C. J., Vocke, C. D., Gurram, S., Turan, S., Kim, Y.-Y., Cawthon, G. M., Sohelian, F., De Val, N., Pfeiffer, R. M., Jailwala, P., Tandon, M., Tran, B., Fan, T. W.- M., Lane, A. N., Ried, T., Wangsa, D., Malayeri Tags: STKE Research Articles Source Type: news

Peninsula biotech Calithera cuts a third of jobs after kidney cancer trial flop
Calithera Biosciences Inc. shed nearly half of its value and will cut about 30 jobs after a mid-stage clinical trial of its marquee drug failed in kidney cancer patients. The South San Francisco company (NASDAQ: CALA) said the job cuts represent 35% of its workforce. The bulk of the job losses would be among those prepping for a potential commercial launch of the drug, called telaglenastat or CB-839. The company's 444-person Phase II study found that advanced or m etastatic renal cell carcinoma… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 4, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Peninsula biotech Calithera cuts a third of jobs after kidney cancer trial flop
Calithera Biosciences Inc. shed nearly half of its value and will cut about 30 jobs after a mid-stage clinical trial of its marquee drug failed in kidney cancer patients. The South San Francisco company (NASDAQ: CALA) said the job cuts represent 35% of its workforce. The bulk of the job losses would be among those prepping for a potential commercial launch of the drug, called telaglenastat or CB-839. The company's 444-person Phase II study found that advanced or m etastatic renal cell carcinoma… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 4, 2021 Category: American Health Authors: Ron Leuty Source Type: news

Browns fan Tom Seipel, battling kidney cancer and in hospice, gets one ‘last-ditch party,’ thanks to his fell
Tom Seipel doesn't know how much longer he has, but he'll get to go to Sunday's Browns-Steelers game thanks to the help of Browns fans... (Source: Reuters: Health)
Source: Reuters: Health - January 3, 2021 Category: Consumer Health News Source Type: news

Cancers in U.S. Teens, Young Adults Have Risen by 30% Since 1970s: Study
  THURSDAY, Dec. 3, 2020 -- Cancer cases among U.S. teens and young adults have shot up 30% since the 1970s, new research reveals. Kidney cancer has risen at the greatest rate, increasing more than threefold among young men and women,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 3, 2020 Category: General Medicine Source Type: news

Cancer cases are rising in adolescents and young adults
(Penn State) Cancer cases in adolescents and young adults have risen by 30% during the last four decades, with kidney cancer rising at the greatest rate, according to researchers at Penn State College of Medicine. The team said further research into screening, diagnosis and treatment are needed to address the growing trend in this age group. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 1, 2020 Category: Cancer & Oncology Source Type: news

$11M NIH grant will fund biomedical research at University of Delaware
(University of Delaware) The National Institutes of Health has renewed a Center of Biomedical Research Excellence (COBRE) grant, worth more than $11 million. The University of Delaware Center is focused on discovery of new molecules that can be used to study and treat diseases such as breast cancer, renal cancer, Crohn's disease, tuberculosis and Legionnaires disease. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 30, 2020 Category: Biology Source Type: news

Cancer Prevention and Screening for Older Adults Cancer Prevention and Screening for Older Adults
This review addresses special considerations regarding prevention and early identification of lung, colorectal, bladder, and kidney cancer for adults aged 65 and older.Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 18, 2020 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

Immunotherapy side effect could be a positive sign for kidney cancer patients
(UT Southwestern Medical Center) An autoimmune side effect of immune checkpoint inhibitor (ICI) drugs could signal improved control of kidney cancer, according to a new study by researchers in UT Southwestern's Kidney Cancer Program (KCP). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 2, 2020 Category: International Medicine & Public Health Source Type: news

UC studies tobacco use, cancer connection
(University of Cincinnati) Researchers at the University of Cincinnati have identified new clues into ways tobacco use impacts patients with kidney cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 20, 2020 Category: International Medicine & Public Health Source Type: news

Is Kidney Cancer Curable?
Title: Is Kidney Cancer Curable?Category: Diseases and ConditionsCreated: 10/14/2020 12:00:00 AMLast Editorial Review: 10/14/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 14, 2020 Category: Cancer & Oncology Source Type: news

Renal Cell Carcinoma Highlights From ESMO 2020 Renal Cell Carcinoma Highlights From ESMO 2020
Dr Robert Motzer reviews key studies on renal cell carcinoma presented at the 2020 ESMO Virtual Congress, including phase 3 trial results showing benefit from combination therapies in advanced RCC.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 8, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Immunotherapy Combo Treats Advanced Kidney Cancer
First results show survival benefit with nivolumab plus cabozantinib versus sunitinib (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 2, 2020 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Conference News, Source Type: news

Immunotherapy Combo Treats Advanced Kidney Cancer
FRIDAY, Oct. 2, 2020 -- Nivolumab combined with cabozantinib is superior to sunitinib alone for the treatment of advanced clear cell renal cell carcinoma, according to a study presented at the annual meeting of the European Society for Medical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 2, 2020 Category: Pharmaceuticals Source Type: news

Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment
Draft Guidance for Industry: Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 1, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Nivo-Cabo Combo Joins Advanced RCC Treatment Ranks Nivo-Cabo Combo Joins Advanced RCC Treatment Ranks
The PD-1 inhibitor/TKI combination is the latest to show superior survival in comparison with sunitinib as first-line therapy for patients with metastatic renal cell carcinoma (RCC).Medscape Medical News (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - September 21, 2020 Category: Urology & Nephrology Tags: Hematology-Oncology News Source Type: news

New first-line treatment option for metastatic kidney cancer
(European Society for Medical Oncology) The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 19, 2020 Category: International Medicine & Public Health Source Type: news

Immunotherapy combination improves outcomes in advanced kidney cancer
(Dana-Farber Cancer Institute) An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial. The pivotal study could lead to a new treatment option for patients with metastatic kidney cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 19, 2020 Category: Cancer & Oncology Source Type: news

Timing of Radiation Plus Immunotherapy Could Be Key to Antitumor Response in Kidney Cancer Timing of Radiation Plus Immunotherapy Could Be Key to Antitumor Response in Kidney Cancer
Appropriate timing of radiation and immunotherapy likely will improve the antitumor response in kidney cancer, a high-throughput analysis suggests.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - September 16, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Novel discovery challenges a current kidney cancer paradigm
(Huntsman Cancer Institute) Newly published research has reversed our understanding of an aspect of kidney tumor growth. Researchers at Huntsman Cancer Institute at the University of Utah discovered that two key proteins have opposite roles than what was previously believed. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 11, 2020 Category: International Medicine & Public Health Source Type: news

'Deep dive' into biology of kidney tumors identifies markers of response to immunotherapy
(Memorial Sloan Kettering Cancer Center) An international team of investigators led by Memorial Sloan Kettering's Robert Motzer has identified biological attributes of kidney cancer tumors that correlate with better responses to immunotherapies and targeted therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 7, 2020 Category: Cancer & Oncology Source Type: news

Kidney cancer symptoms: The warning sign on your testicles
KIDNEY cancer, also called renal cancer, is one of the most common types of cancer in the UK. The symptoms associated with kidney cancer can be vague and attributed to less serious conditions. One sign can be spotted on your testicles. (Source: Daily Express - Health)
Source: Daily Express - Health - August 20, 2020 Category: Consumer Health News Source Type: news

Researchers find link between gut microbiome and cancer treatment outcomes
(City of Hope) City of Hope and TGen have found that greater gut microbial diversity in patients with metastatic kidney cancer is associated with better treatment outcomes on FDA-approved immunotherapy regimens. A potential takeaway: Oncologists might encourage patients to eat a high-fiber diet, including fruits and vegetables high in fructo-oligosaccharides such as bananas, dried fruit, onions, leeks, garlic, asparagus and artichokes, as well as grains with resistant starches such as barley or uncooked potato starch. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 19, 2020 Category: International Medicine & Public Health Source Type: news

New 'two-pronged attack' drug treatment is giving kidney cancer patients longer and healthier lives
The combination of axitnib and avelumab is now available on the NHS in England, after health regulator the National Institute for Health and Care Excellence gave the green light last month. (Source: the Mail online | Health)
Source: the Mail online | Health - August 15, 2020 Category: Consumer Health News Source Type: news

Diabetes Linked to Increased Kidney Cancer Risk, But Only in Slim Diabetes Linked to Increased Kidney Cancer Risk, But Only in Slim
Postmenopausal women with BMIs under 30 are paradoxically more likely to develop kidney cancer than the women of the same age with higher BMIs and larger waists.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 13, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

City of Hope, TGen looking to create personalized roadmaps for treatment of kidney cancer
(City of Hope) Experts at City of Hope and the Translational Genomics Research Institute (TGen) are using one of the world's most comprehensive genomic analysis tools to map out personalized treatment plans for metastatic kidney cancer patients. " The hope is to one day identify patients who will benefit from immunotherapy and those who will not. Eventually we may be able to distinguish which patient is better suited for other treatments, like targeted therapy, " said Sumanta Pal, M.D. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 22, 2020 Category: International Medicine & Public Health Source Type: news

ECR 2020: Radiologists, data scientists needed for AI
Greater involvement by radiologists and more help from data scientists are...Read more on AuntMinnie.comRelated Reading: ECR 2020: COVID-19 greatest health threat since Spanish flu SNMMI 2020: AI can aid in diagnosis of Parkinson's disease Are U.S. medical students avoiding radiology due to AI? AI could help radiologists better detect kidney cancer Coronavirus fears prompt rescheduling of ECR 2020 to July (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 17, 2020 Category: Radiology Source Type: news

Study Supports Changing Classification of Renal Cell Carcinoma Study Supports Changing Classification of Renal Cell Carcinoma
The definition of stage 4 renal cell carcinoma should be expanded to include lymph node-positive stage 3 disease, according to a new study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 7, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Certain pesticides linked to kidney cancer in agricultural workers
New findings from the Agricultural Health Study suggest exposure to certain pesticides may increase risk of renal cell carcinoma. (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - July 6, 2020 Category: Environmental Health Source Type: news

AI could help radiologists better detect kidney cancer
Artificial intelligence (AI) used with CT data could help abdominal radiologists...Read more on AuntMinnie.comRelated Reading: AI algorithm can help in incidental detection of PE SIIM 2020: COVID-19 could accelerate nonrad POCUS use SIIM 2020: The future is now for 3D imaging SIIM 2020: How to create robust radiology AI algorithms SIIM 2020: Human element shouldn't be neglected with AI (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 6, 2020 Category: Radiology Source Type: news

Liquid Biopsy Promising in Spotting Kidney Cancer Liquid Biopsy Promising in Spotting Kidney Cancer
An assay employing plasma and urine cell-free DNA methylomes is capable of classifying patients across all stages of renal-cell carcinoma, according to preliminary studies.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 2, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Biomarker test highly accurate in detecting early kidney cancer
(Dana-Farber Cancer Institute) A novel liquid biopsy method can detect kidney cancers with high accuracy, including small, localized tumors which are often curable but for which no early detection method exists, say scientists from Dana-Farber Cancer Institute. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 22, 2020 Category: Cancer & Oncology Source Type: news

Good Survival Rates After Percutaneous Cryoablation for Early Renal Cell Carcinoma Good Survival Rates After Percutaneous Cryoablation for Early Renal Cell Carcinoma
Percutaneous cryoablation yields survival rates at least as good as those with nephrectomy in patients with stage 1 renal cell carcinoma, according to a prospective observational study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 11, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Oncotarget: Hyperprogression to immune blockade followed by a response with cabozantinib
(Impact Journals LLC) Volume 11, Issue 22 of @Oncotarget reported that more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 10, 2020 Category: Cancer & Oncology Source Type: news

Percutaneous Cryoablation Treats Early-Stage Kidney Cancer
TUESDAY, June 9, 2020 -- Percutaneous cryoablation (PCA) for stage I renal cell carcinoma (RCC) results in good outcomes, with a 10-year disease-specific survival of 94 percent, according to a study published online June 9 in Radiology. John... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 9, 2020 Category: Pharmaceuticals Source Type: news

Cryoablation comparable to surgery for kidney cancer
Percutaneous cryoablation is comparable to surgery for treating kidney cancer,...Read more on AuntMinnie.comRelated Reading: 3D VR models improve kidney-sparing surgery outcomes How can 3D printing improve kidney cancer surgery? AR, 3D printing aid presurgical planning for kidney cancer Personalized treatment fights early-stage kidney cancer Do more CT scans lead to more kidney surgeries? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 9, 2020 Category: Radiology Source Type: news

Freezing Kidney Tumors Offers Similar Survival Rate, Fewer Complications
Cryoablation offers patients with early-stage kidney cancer comparable results to surgery. (Source: Diagnostic Imaging)
Source: Diagnostic Imaging - June 9, 2020 Category: Radiology Authors: Whitney J. Palmer Tags: CT Kidney Cancer Source Type: news

Cryoablation comparable to surgery for treating early-stage kidney cancer
(Radiological Society of North America) A minimally invasive procedure that destroys cancer cells by freezing them is as effective as surgery for treating early-stage kidney cancer, offering similar 10-year survival rates with a lower rate of complications, according to a new study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 9, 2020 Category: Cancer & Oncology Source Type: news

Elizabeth Plimack, MD, MS, Discusses Subsequent Therapy in Advanced RCC
Elizabeth Plimack, MD, MS, discussed the role of subsequent immunotherapy when analyzing the primary endpoint of overall survival for axitinib and pembrolizumab over sunitinib in patients with advanced renal cell carcinoma evaluated in the updated analysis of KEYNOTE-426. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2020 Category: Cancer & Oncology Authors: Elizabeth R. Plimack, MD, MS Source Type: news

UT Health San Antonio study shows Nox4 protein may predict untreatable kidney cancer
(University of Texas Health Science Center at San Antonio) University of Texas Health Science Center at San Antonio researchers confirmed the role of a certain protein, Nox4, in the development of high-grade kidney cancer. The researchers also showed that a higher level of the protein can be used as a marker to predict in humans which tumors will develop treatment resistance and progress more rapidly. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2020 Category: International Medicine & Public Health Source Type: news

Health Experts Criticize EPA ’s Asbestos Draft Risk Evaluation
Doctors, scientists and occupational health experts from across the country are openly criticizing the U.S. Environmental Protection Agency’s recent asbestos draft risk evaluation. At a virtual press conference arranged by the Asbestos Disease Awareness Organization last week, speakers labeled the asbestos evaluation inadequate and in need of serious revision. The year-long evaluation was required as part of the Frank R. Lautenberg Chemical Safety for the 21st Century Act, which was passed in 2016. It amended the original Toxic Substances Control Act, the country’s primary chemicals management law. “I am...
Source: Asbestos and Mesothelioma News - June 2, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Eric Jonasch, MD, on Next Steps in MK-6482 in VHL Disease –Associated RCC
The MD Anderson Cancer Center expert discussed next steps for those with von Hippel-Lindau disease –associated renal cell carcinoma being treated with the HIF-2a Inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2020 Category: Cancer & Oncology Authors: Eric Jonasch, MD Source Type: news

Eric Jonasch, MD, Discusses Use of MK-6482 in VHL Disease –Associated Kidney Cancer
The HIF-2a Inhibitor, MK-6482, induced clinical responses among patients with von Hippel-Lindau disease –associated renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Eric Jonasch, MD Source Type: news

Study reveals factors influencing outcomes in kidney cancer treated with immunotherapy
(Dana-Farber Cancer Institute) By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2020 Category: Cancer & Oncology Source Type: news

Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC
When compared with sorafenib, tivozanib showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

Savolitinib Induces Encouraging Efficacy, Safety in MET-Driven Papillary Renal Cell Carcinoma
A phase III study presented the 2020 ASCO Virtual Scientific Program showed encouraging efficacy data suggesting savolitinib could be used to treat patients with MET-driven papillary renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Novel targeted drug induced positive response for VHL-associated kidney cancer
(University of Texas M. D. Anderson Cancer Center) In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)-associated renal cell carcinoma (RCC). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 28, 2020 Category: Cancer & Oncology Source Type: news

Tivozanib Induces Durable Response Among Patients with Advanced Renal Cell Carcinoma
The VEGF TKI induced durable responses and favorable tolerability in patients with relapsed/refractory RCC. (Source: CancerNetwork)
Source: CancerNetwork - May 20, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news